Cristin-resultat-ID: 883384
Sist endret: 28. oktober 2016 16:36
NVI-rapporteringsår: 2011
Resultat
Vitenskapelig artikkel
2013

Cost Effectiveness of Drug-Eluting Stents as Compared With Bare Metal Stents in Patients With Coronary Artery Disease

Bidragsytere:
  • Torbjørn Wisløff
  • Dan Atar og
  • Ivar Sønbø Kristiansen

Tidsskrift

American Journal of Therapeutics
ISSN 1075-2765
e-ISSN 1536-3686
NVI-nivå 1

Om resultatet

Vitenskapelig artikkel
Publiseringsår: 2013
Volum: 20
Hefte: 6
Sider: 596 - 601

Importkilder

Isi-ID: 000329937100003

Beskrivelse Beskrivelse

Tittel

Cost Effectiveness of Drug-Eluting Stents as Compared With Bare Metal Stents in Patients With Coronary Artery Disease

Sammendrag

The aim of this study was to estimate the incremental cost effectiveness of replacing bare metal stents (BMS) by drug-eluting stents (DES) when using trial data and registry data. We developed a Markov model (model of cost effectiveness of coronary artery disease) in which 60-year-old patients started by undergoing percutaneous coronary intervention for acute or subacute coronary artery disease. The patients are followed until death or 100 years of age. Data on the occurrence of events (revascularization, acute myocardial infarction, and death) were based on Scandinavian registry data. Separate analyses were conducted with data on effectiveness based on randomized controlled trials and patient registries. On using trial data, it was found that sirolimus-eluting stents (SES) yield 0.003 greater life expectancy and $3300 lower costs than do BMS (dominant strategy). Paclitaxel-eluting stents (PES) yield 0.148 more life years than do SES at additional lifetime costs of $2800 ($21,400 per life year gained). On using registry data, the cost per life year gained was found to be $4900 when replacing BMS with DES. Probabilistic sensitivity analyses, on the other hand, indicate that PES only has a 50%-75% probability of being cost effective, regardless of the type of effectiveness data. DESs are cost effective with current willingness to pay for life year gains. Whether PES or SES is the most effective DES remains uncertain.

Bidragsytere

Aktiv cristin-person

Torbjørn Wisløff

  • Tilknyttet:
    Forfatter
    ved Avdeling for metodeutvikling og analyse ved Folkehelseinstituttet
  • Tilknyttet:
    Forfatter
    ved Avdeling for helseledelse og helseøkonomi ved Universitetet i Oslo
Aktiv cristin-person

Dan Atar

  • Tilknyttet:
    Forfatter
    ved Hjertemedisinsk avdeling ved Universitetet i Oslo
  • Tilknyttet:
    Forfatter
    ved Hjertemedisinsk avdeling ved Oslo universitetssykehus HF

Ivar Sønbø Kristiansen

  • Tilknyttet:
    Forfatter
    ved Avdeling for helseledelse og helseøkonomi ved Universitetet i Oslo
1 - 3 av 3